InMed Pharmaceuticals (INM) Operating Leases (2020 - 2026)

InMed Pharmaceuticals has reported Operating Leases for 7 years, with the latest figure at $30766.0 in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 92.66% year-over-year to $30766.0; the trailing twelve-month figure through Mar 2026 stood at $30766.0 (down 92.66% YoY), and the FY2025 full-year result was $305755.0, down 52.59% from the prior year.
• Operating Leases for Q1 2026 stood at $30766.0, down from $123827.0 in the prior quarter.
• The five-year high for Operating Leases was $1.2 million in Q4 2023, with the low at $15994.0 in Q2 2023.
• Historically, Operating Leases has averaged $384609.6 across 5 years, with a median of $305755.0 in 2025.
• Annual changes were most pronounced in 2023 — Operating Leases sank 95.89% — and 2024, when it jumped 3931.92%.
• InMed Pharmaceuticals' Operating Leases stood at $183902.0 in 2022, then soared by 534.56% to $1.2 million in 2023, then sank by 54.65% to $529248.0 in 2024, then sank by 76.6% to $123827.0 in 2025, then tumbled by 75.15% to $30766.0 in 2026.
• The last three Operating Leases figures came in at $30766.0 (Q1 2026), $123827.0 (Q4 2025), and $215478.0 (Q3 2025), per Business Quant data.